LGLihu Gu

Lihu Gu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lihu Gu has a total of 118 co-authors. Here are the top co-authors by number of shared publications:

  • Ping Chen

    Department of General Surgery, Ningbo No. 2 Hospital, Ningbo, Zhejiang 315010, P.R. China

    8 shared publications
  • Hepan Zhu

    Department of General Surgery, Zhejiang University School of Medicine Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China

    5 shared publications
  • Zefeng Shen

    Department of General Surgery, Zhejiang University School of Medicine Sir Run Run Shaw Hospital, Hangzhou, China

    5 shared publications
  • Danyi Mao

    Zhejiang Chinese Medical University, Zhejiang, Hangzhou, China

    4 shared publications
  • Feng Wu

    Department of General Surgery, Ningbo No. 2 Hospital, Ningbo, Zhejiang 315010, P.R. China

    4 shared publications
  • Junhai Pan

    Department of General Surgery, Zhejiang University School of Medicine Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China

    4 shared publications

Latest Publications

  • Open Access

    Safety analysis of omitting axillary lymph node dissection in early-stage breast cancer with 1–2 sentinel lymph nodes macro-metastases: a meta-analysis

    by Yu Chen, Xiaoming Zhang, Qingping Wu, Shanshan Gao, Lu Wang, Minxia Zeng, Lihu Gu, Changrui Sheng

    Background: Currently, the axillary management strategy of omitting axillary lymph node dissection (ALND) in early-stage breast cancer (BC) patients with cT1-2, clinically node-negative (cN0), and sentinel lymph node biopsy (SLNB) revealing 1–2 sentinel lymph nodes (SLNs) macro-metastases remains controversial. This study aims to systematically evaluate the safety of omitting ALND in this population.Methods: This study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and was registered with the registration number: CRD42025645388. A systematic literature search was conducted across five electronic databases (PubMed, Web of Science, Cochrane Library, Ovid Medline, and Embase) from inception through December 2024. Randomized controlled trials (RCTs) and cohort studies meeting the predefined eligibility criteria were included. Primary outcomes included disease-free survival (DFS) and overall survival (OS). The association between ALND omission and long-term outcomes was assessed using pooled hazard ratios (HRs) with 95% confidence intervals (CIs).Results: Fifteen studies (6 RCTs, 9 cohort studies) involving 33,599 patients in the SLNB-only group and 95,711 controls receiving SLNB+ALND were analyzed. No significant differences in DFS (HR = 0.99, 95%CI:0.85-1.14, p=0.857) or OS (HR = 1.03, 95%CI: 0.92-1.14 p=0.251) were observed in both groups. Subgroup analyses by follow-up duration (5-years and 10-years), study design (RCTs and cohort studies), and region (Eastern and Western) showed no survival differences between the experimental and control groups. (all p values are greater than 0.05).Conclusion: Omitting ALND is safe for early-stage BC patients with cT1-2, cN0, and 1–2 SLNs macro-metastases.Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42025645388.


  • Open Access

    Clinical importance of E‑cadherin deficiency in resectable gastric cancer: A nested case‑control study

    by Cheng Zheng, Min Dai, Dongying Wang, Xingchen Liu, Zhiyi Xiang, Anyi Xu, Ping Chen, Feng Wu, Yuan Yuan, Shengqiang Ji, et al.

    The prognosis of gastric cancer (GC) remains unsatisfactory despite advancements in diagnosis and treatment. Epithelial‑mesenchymal transition‑induced decreased cell‑cell adhesion, often associated with E‑cadherin deficiency, serves a crucial role in tumor invasion and metastasis. However, the relationship between E‑cadherin deficiency and GC prognosis is unclear. The present study aimed to explore the association between E‑cadherin deficiency and the prognosis of resectable GC. The nested case‑control study involved prospective data collection and retrospective analysis. Between January 2013 and December 2022, a total of 1,574 patients treated for GC were eligible for prognostic analysis (104 in the E‑cadherin deficiency group and 1,470 in the E‑cadherin expression group). Logistic regression analysis was utilized to evaluate the univariate and multivariate associations between clinicopathological factors and E‑cadherin deficiency. Propensity score matching analysis at a ratio of 1:4 was performed. Kaplan‑Meier curves were employed to analyze the relationship between the prognosis of the E‑cadherin deficiency group and the E‑cadherin expression group. There were 104 cases of E‑cadherin deficiency, accounting for an incidence of 6.6%. The results of the analysis revealed that a family history of GC [odds ratio (OR), 7.60; P<0.001], poorly differentiated tumors (OR, 8.67; P<0.001), perineural invasion (OR, 1.63; P=0.030) and elevated carcinoembryonic antigen (CEA) (OR, 1.83; P=0.034) were independent risk factors for E‑cadherin deficiency in all enrolled patients. Following propensity score matching analysis, 86 cases in the E‑cadherin deficiency group and 344 cases in the E‑cadherin expression group were included. Survival analysis demonstrated no statistically significant difference in 5‑year disease‑free survival rates between the E‑cadherin deficiency and expression groups (P=0.590). Similarly, the 5‑year overall survival rates were comparable between the two groups (P=0.863). In summary, E‑cadherin deficiency is associated with a family history of GC, poorly differentiated tumors, perineural invasion and elevated CEA levels. However, E‑cadherin deficiency does not impact the prognosis of resectable GC.


  • Open Access

    Efficacy of Glucagon-like Peptide-1 Receptor Agonists in Overweight/Obese and/or T2DM Adolescents: A Meta-analysis Based on Randomized Controlled Trials

    by Min Dai, Senjie Dai, Lihu Gu, Zhiyi Xiang, Anyi Xu, Siyu Lu, Yang Yang, Cong Zhou

    Objective: The aim of this meta-analysis was to investigate the effect of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on blood glucose and weight in adolescents with overweight/obesity and/or type 2 diabetes mellitus (T2DM) aged <18 years. METHODS: PubMed, Embase, Web of Science, and Cochrane Library were searched for all randomized controlled trials (RCTs) up to August 2023 comparing GLP-1RAs with placebo in overweight/obese and/or T2DM adolescents and extracted relevant data for meta-analysis. RESULTS: Fourteen RCTs were included in the meta-analysis with a total of 1,262 participants. Results revealed that the GLP-1RAs group had a more significant reduction in glycosylated hemoglobin A1c (HbA1c; risk difference (RD)=-0.34%, p<0.001) than the control group. However, there was no difference in fasting plasma glucose [fasting plasma glucose (FPG); RD=-2.07 mg/dL, p=0.065] between the two groups. Nonetheless, the experimental group that received exenatide showed no significant reduction in HbA1c (p=0.253) and FPG (p=0.611) between the two groups. The GLP-1RAs group had a more significant decline in body weight (RD=-4.28 kg, p=0.002) and body mass index (BMI) (RD=-1.63 kg/m(2), p=0.002) compared to the control group. The experimental group was given liraglutide (RD=-2.31 kg, p=0.038) or exenatide (RD=-2.70 kg, p<0.001). Compared to the control group, the experimental group had a more significant drop in body weight than the control group. However, for the experimental group that received liraglutide, the BMI had a no significant reduction between the two groups (RD=-0.81 kg/m(2), p=0.260). For the experimental group using exenatide, BMI declined more significantly in the intervention group than in the control group (RD=-1.14 kg/m(2), p<0.001). DISCUSSION AND CONCLUSION: This study showed that GLP-1RAs reduced HbA1c, FPG, and weight loss in overweight/obese and/or T2DM adolescents. Liraglutide was better than exenatide in terms of glucose reduction. Nevertheless, in terms of weight control, exenatide was more effective than liraglutide.


  • Open Access

    Exploring Individualized Follow-up of Gastric Cancer After Radical Surgery Based on pTNM Stage: A Retrospective Cohort Study From China

    by Cheng Zheng, Mengyi Qian, Tongmin Huang, Xingchen Liu, Xiangman Zeng, Xiaotong Chen, Yan Shen, Ping Chen, Feng Wu, Lihu Gu

    Background: Patients with gastric cancer (GC) who underwent radical surgery require long-term follow-up (usually 5 years). The purpose of this study was to explore individualized follow-up strategies for patients with GC.Methods: This is a retrospective cohort study that established a clinicopathologic database of patients who underwent gastrectomy from January 2010 to December 2020 at Ningbo No. 2 Hospital. Follow-up was performed until March 2023. The rate of new-onset recurrence of patients with GC was explored annually according to different pTNM stages, defining a recurrence rate of less than 1% as adequate follow-up time.Results: Of the 1606 patients who were eligible, the total number of patients who completed the 5- and 10-year follow-up was 1107 and 586, respectively. A total of 444 cases were diagnosed with recurrence. The recurrence rate for stage IA patients was consistently less than 1% during the follow-up time. The adequate follow-up time (the rate of new-onset recurrence less than 1%) was 5 years for stage IB and IIA patients, and 8 years for stage IIB and IIIA patients, respectively. In contrast, stage IIIB patients were always at risk of recurrence during the follow-up time (>1%). Time to a new recurrence rate for stage IIIC patients was 6 years.Conclusion: Among patients who underwent radical gastrectomy, the rate of new-onset recurrence varied among patients with different pTNM stages. This study suggests that the follow-up of GC can be individualized and refer to pTNM stage.


  • Transjugular intrahepatic portosystemic shunt for pyrrolidine alkaloids-induced hepatic sinusoidal obstruction syndrome: a retrospective cohort study

    by Tongmin Huang, Xingfen Zhang, Kun Yan, Dandi Lou, Yujing He, Senjie Dai, Dingcheng Zheng, Ping Chen, Feng Wu, Lihu Gu

    Background: This study aimed to investigate the efficacy and safety of transjugular intrahepatic portosystemic shunt (TIPS) in the treatment of patients with pyrrolidine alkaloids-induced hepatic sinusoidal obstruction syndrome (PA-HSOS). Methods: Patients diagnosed with PA-HSOS and treated in Ningbo No.2 Hospital between November 2017 and October 2022 were enlisted in this retrospective cohort study. Results: This cohort comprised a total of 22 patients with PA-HSOS, of which 12 patients received TIPS treatment and 10 patients experienced conservative treatment. The median follow-up duration was 10.5 months. Baseline characteristics existed with no significant difference between the two groups. No operation failures or any TIPS-associated intraoperative complications were observed after TIPS. In the TIPS group, the portal venous pressure was substantially decreased from 25.3 ± 6.3 mmHg to 14.4 ± 3.5 mmHg after TIPS (P = 0.002). Compared with preoperative, the ascites after TIPS were significantly subsided (P = 0.001) and there existed a considerable decrease in Child-Pugh score. At the end of follow-up, 5 patients died, involving 1 in the TIPS group and 4 in the conservative treatment group. The median survival time was 13 (3–28) months in the TIPS group and 6.5 (1–49) months in the conservative treatment group, respectively. The survival analysis demonstrated that the total survival time of TIPS group was longer than that of the conservative treatment group, no statistical significance was observed (P = 0.08). Conclusion: TIPS may be a secure and effective therapeutic strategy for PA-HSOS patients who do not respond to conservative treatment.


  • Association between statins’ exposure with incidence and prognosis of gastric cancer: an updated meta‐analysis

    by Dandi Lou, Rongrong Fu, Lihu Gu, Hui Su, Like Guan

    Previous research has revealed the role of statins in cancer prevention and treatment. This study aimed to determine the relationship between statins exposure and the incidence and prognosis of gas...


  • Open Access

    Suppression of the transforming growth factor-β signaling pathway produces a synergistic effect of combination therapy with programmed death receptor 1 blockade and radiofrequency ablation against hepatic carcinoma in mice

    by Xiaoxiang Fan, Lihu Gu, Shuyi Lv, Meiwu Zhang, Luhui Zhuang, Yan Zhang, Ping Chen

    Primary liver cancer (PLC) significantly affects the health of patients globally owing to its high morbidity and low survival rate. Radiofrequency ablation (RFA) has recently been introduced for the clinical treatment of PLC. However, significant immunosuppressive effects are induced by RFA, which limits its application. This study aimed to explore the potential of combination therapy with RFA by investigating the effects of siRNAs against programmed death receptor 1 (PD-1) and transforming growth factor-β (TGF-β) on the antitumor effect induced by RFA. We observed that compared with si-NC, cell viability was reduced, apoptosis rate was elevated, release of inflammatory factors and percentage of CD3+CD8+ cells were increased, and the PI3K/AKT/mTOR pathway was repressed in the co-culture of RFA-treated H22 cells and CD8+ T cells by transfection with si-PD-1 and si-TGF-β; these effects were further enhanced by co-transfection with si-PD-1 and si-TGF-β. Additionally, in H22 cell xenograft-bearing mice treated with RFA, compared with the si-NC group, repressed tumor growth, prolonged survival, increased production of inflammatory factors and expression of CD3 and CD8 in tumor tissues, and downregulation of the PI3K/AKT/mTOR pathway were observed in the si-PD-1 and si-TGF-β groups; these effects were further enhanced in the si-PD-1 + si-TGF-β group. Taken together, our data revealed that suppression of the TGF-β signaling pathway produced a synergistic antitumor effect of combination therapy with PD-1 blockade and RFA against PLC.


  • HIFU for the treatment of difficult colorectal liver metastases with unsuitable indications for resection and radiofrequency ablation: a phase I clinical trial

    by Tong Yang, Derry Minyao Ng, Nannan Du, Ning He, Xiaoyu Dai, Ping Chen, Feng Wu, Bo Chen, Xiaoxiang Fan, Kun Yan, et al.

    Background The goal of this study is to evaluate the safety and efficacy of high intensity focused ultrasound (HIFU) for patients with colorectal liver metastases (CRLM) but were contraindicated for resection and radiofrequency ablation. Methods Patients between 20 and 80 years of age with 1–3 liver metastases from colorectal cancer were selected. Included patients have had their primary lesions removed with no evidence of extrahepatic metastasis prior to the study. Ultrasound-guided HIFU was employed and target regions’ ablation was achieved with repeated sonications from the deep to shallow regions of the tumors section by section. Results Thirteen patients were enrolled. The most common adverse events (AEs) were pain (n = 8), followed by fatigue (n = 7), increased aspartate aminotransferase (AST) (n = 7), increased alanine aminotransferase (ALT) (n = 5), and skin edema (n = 4). No grade ≥ 3 AEs occurred and while most patients (76.9%) achieved a complete response, three patients achieved a partial response. The objective response rate was 100% after the first HIFU treatment. Nine patients relapsed but the tumors were mostly isolated to the liver (8/9). The median follow-up period was 25 months. The 2-year progression-free survival (PFS) was 16.7%, and the median PFS was 9 months. Notably, the 2-year overall survival (OS) was 77.8%, and the median OS was 25 months. Conclusion This study indicates that the HIFU treatment is safe, is able to achieve a good tumor response rate and long-term prognosis even when the foci were in high-risk locations, and should be considered for patients who were considered unsuitable for other local treatments.


  • Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: A systematic review and meta‐analysis

    by Lihu Gu, Qigu Yao, Zefeng Shen, Ying He, Derry Minyao Ng, Tong Yang, Bangsheng Chen, Ping Chen, Feiyan Mao, Qili Yu

    Background and Aim: Studies had shown that tenofovir (TDF) and entecavir (ETV) are widely used as the first‐line therapy to inhibit hepatitis B virus replication, which can reduce the risk of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients, but it was unclear which nucleos(t)ide analogue was most effective. Therefore, we performed a meta‐analysis and a systematic review to compare the incidence of HCC in CHB patients who are either on TDF or ETV.Methods: For this study, the following databases were searched for clinical trials published from its inception until November 2019: PubMed, Web of Science, MEDLINE, Embase, and Cochrane Library.Results: A total of 11 eligible studies were selected, including 70 864 patients. The meta‐analysis showed that TDF was superior to ETV with regard to the incidence of HCC, the incidence of death or transplantation, and virologic response. There were no significant differences in terms of biochemical response and loss of seroconversion response among the entire cohort.Conclusions: The conclusion was that CHB patients treated with TDF had a reduced incidence of HCC compared with patients treated with ETV.


  • Magnitude of benefit of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for malignant tumor: A meta-analysis

    by Lihu Gu, Nannan Du, Qiong Jin, Shengnan Li, Laidi Xie, Jiahang Mo, Zefeng Shen, Danyi Mao, Jia Ji, Parikshit Asutosh Khadaroo, et al.